MAZE Healthcare

Maze Therapeutics, Inc.

$32.25+6.19%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 1.8B USD
Enterprise value: 1.2B USD
Full-time employees: 141

Overall health

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Not enough data: growth

Would rank #798 of 1,157 fully scored healthcare companies (bottom 32%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Maze Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
Maze Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

42/ 100

Oct 5 42 → Nov 4 42

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-7.5%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-10.2%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-6.0%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield25.3%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

20/100

Weak

2/3 inputs reported · Partial data

Why

Weaker than most peers on:

▼ ROIC
▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating marginUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0706 · MAD: 0.1217

Return on assets-25.1%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -4.99Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-39.7%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -4.43Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin100.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-29.5%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

2/3 inputs reported · Partial data

Why

Stronger than most peers on:

▲ Current ratio
▲ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

BetaUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.6250 · MAD: 0.3380

Current ratio18.31×

SEC filings · latest balance sheetOutlier capped at sector 5th/95th percentile33% base weight · Z-score 11.07Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.09×

SEC filings · latest balance sheetReported value33% base weight · Z-score 0.66Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Maze Therapeutics

Is Maze Therapeutics getting weaker?: A comparison of its latest SEC filing with the previous one isn't available yet. Its overall score is unchanged at 42/100 since Oct 28, 2026.
How is Maze Therapeutics valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -7.5% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -7.5% vs peers 1.5% (weaker than 100% of peers).
Is Maze Therapeutics growing?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How profitable is Maze Therapeutics?: Less profitable than most of its peers. Profitability scores 20/100 against 1,393 healthcare peers. Return on invested capital -39.7% vs a peer median of 4.7% (weaker than 86% of peers).Return on invested capital -39.7% vs peers 4.7% (weaker than 86% of peers).
How risky is Maze Therapeutics?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 18.31× vs a peer median of 2.59× (stronger than 95% of peers).Current ratio 18.31× vs peers 2.59× (stronger than 95% of peers). A relative measure, not a bankruptcy probability.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2024	FY 2025	Change
Operating margin	34.4%	—	—
Net margin	31.2%	—	—
Return on assets (ROA)	21.7%	-33.0%	▼ 55 pts
Return on equity (ROE)	—	-36.9%	—
Free cash flow margin	44.7%	—	—
Current ratio	9.76×	15.50×	▲ 59%

MAZE price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Not enough data: growth

Would rank #798 of 1,157 fully scored healthcare companies (bottom 32%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Maze Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

Maze Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about Maze Therapeutics

Is Maze Therapeutics getting weaker?

A comparison of its latest SEC filing with the previous one isn't available yet. Its overall score is unchanged at 42/100 since Oct 28, 2026.

How is Maze Therapeutics valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -7.5% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -7.5% vs peers 1.5% (weaker than 100% of peers).

Is Maze Therapeutics growing?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How profitable is Maze Therapeutics?

Less profitable than most of its peers. Profitability scores 20/100 against 1,393 healthcare peers. Return on invested capital -39.7% vs a peer median of 4.7% (weaker than 86% of peers).Return on invested capital -39.7% vs peers 4.7% (weaker than 86% of peers).

How risky is Maze Therapeutics?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 18.31× vs a peer median of 2.59× (stronger than 95% of peers).Current ratio 18.31× vs peers 2.59× (stronger than 95% of peers). A relative measure, not a bankruptcy probability.

Key ratios

FY 2024

FY 2025

Change

Operating margin

34.4%

—

Net margin

31.2%

—

Return on assets (ROA)

21.7%

-33.0%

▼ 55 pts

Return on equity (ROE)

—

-36.9%

—

Free cash flow margin

44.7%

—

Current ratio

9.76×

15.50×

▲ 59%